Compare ELSE & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | ABP |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 18.8M |
| IPO Year | N/A | N/A |
| Metric | ELSE | ABP |
|---|---|---|
| Price | $4.40 | $5.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 28.9K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $9,787,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.90 | ★ N/A |
| Revenue Growth | 5.36 | ★ 50.00 |
| 52 Week Low | $3.65 | $4.55 |
| 52 Week High | $5.50 | $153.90 |
| Indicator | ELSE | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 55.40 |
| Support Level | $4.48 | $5.55 |
| Resistance Level | $4.70 | $6.38 |
| Average True Range (ATR) | 0.06 | 0.55 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 0.00 | 32.25 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.